MARIE STOPES INTERNATIONAL
Children by choice, not chance

RH Supplies: Insights from an INGO

Marie Stopes International

Jason Bower

Senior Pharmaceutical Advisor

Seminar on Family Planning Medicines and Supplies

Nov 2017



Marie Stopes International – what we do

What we do

We provide sexual and reproductive healthcare to millions of under-served women around the world.

Services

Family planning

Maternal health

HIV / STIs

Safe abortion and post-abortion care

Delivery

Clinical outreach

Social franchising

Centres

Reaching the under-served

Providing choice

Our work in family planning

Going the extra mile

Providing services on outreach

Social marketing

We distribute our own brand of high quality and affordable condoms, contraceptive pills and other contraceptive products through pharmacies, community-based distributors and other private providers.

Insight #1

There are lots of poor quality RH products

Misoprostol samples % Content vs Time

Courtesy of Peter Hall / Concept Foundation / HCI Lab



Example: India public sector



Source: ***India National Drug Survey 2014-16***

EDITION AU

HUFFPOST

NEWS POLITICS ENTERTAINMENT SPORT REFRESH TECH FOOD MORE

HEALTH

Almost Half Of Pregnancy Tests Removed From Sale After Sweeping Review

The tests were producing false negative results.

24/03/2017 9:42 AM AEDT | **Updated** 24/03/2017 12:27 PM AEDT

Lara Pearce
Associate Editor, HuffPost Australia

LUFLOR VIA GETTY IMAGES

Seventeen pregnancy tests have been removed from sale following an investigation by the Therapeutic Goods Administration.

An alarming 17 pregnancy test brands have ceased sale in Australia or been recalled following a sweeping review of all home pregnancy tests available.

The review, conducted by the Therapeutic Goods Administration (TGA), found that several of the common pregnancy tests available to Australian women were giving false negative results -- indicating the woman was not pregnant, when she in fact was.

TRENDING

- Someone Was Trying To Sell Nude Photos Of Sia So She Tweeted One Herself
- Kate Winslet Kissed Allison Janney At The Hollywood Film Awards
- Scott Ludlam Is Having Lots Of Fun With The Citizenship Crisis

Insight #2

Whilst NDRAs have strengthened standards, lower quality RH products have entered LMIC markets

Insight #3

Higher internal standards and more oversight needed for our key products

MSI Policy on Product Quality v4



MSI Policy on Product Quality

Contents

Name of Policy or Protocol:	Marie Stopes International Policy on Product Quality
Version:	V4.0
Applies to:	All country programmes: CDs; SMTs; Designated Leads for Clinical Quality; Procurement & Logistics Staff; Channel Leads; Providers
Ratified by:	MSI Executive Committee October 2016
Issue Date:	December 2016
Review Date:	December 2018

Product categories & minimum QA standards

PRODUCT TYPE	Key SRH Products	Key Ancillary Drugs	Other Ancillary Products
PRODUCTS	❖ Contraceptive devices ❖ Contraceptive medicines ❖ Medicines for safe abortion ❖ MVA equipment ❖ Pregnancy and HIV tests ❖ Metal surgical instruments	❖ Oxytocics ❖ Magnesium sulphate inj ❖ Anaesthetics ❖ Analgesics ❖ Antibacterials, antiretrovirals, antimalarials ❖ All sterile injectable products	❖ Antifungals and anthelminthics ❖ Other supportive medicines ❖ Other medical consumables such as gloves, syringes, sutures etc
MINIMUM STANDARD	• WHO prequalified • UNFPA ERP 1/2 • SRA approved • **MSI QARMA** approved • ISO & CE certification + tech requirements for devices	• MSI approved international wholesalers • Manufacturer listed in MSI List of Recommended Manufacturers	• No mandatory standard
	GLOBAL PROCUREMENT	LOCAL PROCUREMENT	LOCAL PROCUREMENT

Q-Trak tool


Q-Trak
Home
My Products
My Submissions
Key SRH List
Ancillary Lists
How to / FAQ
Hello, jason
Log Out
My Products
List below the products which are currently in use in your programme. You can add new products, modify products you have already entered, and delete products which you are no longer using. You should include all contraceptive, misoprostol, and mifepristone products. Once you have completed entering all your products, click "Submit" to create your new submission.
Afghanistan
Add new product
Product Type
Injectable - DMPA
Your Product Name
Depo Provera
Manufacturer Name
Pfizer / Pharmaci
Supplied By
MSI GP&L
Manufacturer Site Address
Rijksweg, Puurs, Belgium
Comments (optional)
Product Details
depomedroxyprogesterone ace
DFID-funded
WHO or SRA Approved
#7
Save
Delete
Product Type
Misoprostol tablets
Your Product Name
MISOCLEAR
Manufacturer Name
ACME Formulatic
Supplied By
MSI GP&L
Manufacturer Site Address
Ropar Road, Nalagarh, Dist. Solan HP, India
Comments (optional)
Product Details
misoprostol 200mcg tablets (Mi
DFID-funded
WHO or SRA Approved
#6
Save
Delete
Product Type
Implant
Your Product Name
Jadelle
Manufacturer Name
Bayer Schering F
Supplied By
Govt: non-donor
Manufacturer Site Address
Turku, Finland
Comments (optional)
Product Details
levonorgestrel 2x75mg implant
DFID-funded
WHO or SRA Approved
#5
Save
Delete

Insight #4

WHO PQ currently covers a limited number of RH products



Q-Trak Home My Products My Submissions Key SRH List Ancillary Lists How to / FAQ Hello, jason Log Out

MSI List of Recommended Manufacturers for Ancillary Medicines

Note:

1. The manufacturers listed below have undergone satisfactory GMP assessment by an approved inspection body and are considered generally acceptable for general medicines
2. Note however that the specific products manufactured by the listed Recommended Manufacturers have not been individually assessed, so satisfactory Quality Assurance can not be guaranteed
3. Recommended sources also include all medicines manufactured by multinational PhRMA member companies, such as GSK, Novartis, Merck, Bayer, etc, including their local manufacturing plants
4. These lists are extracted from QUAMED Database and are confidentially for MSI programme use only

Search

Manufacturer Name	Manufacturer Country	Manufacturer Address
ABBOTT HEALTHCARE PRIVATE LTD	India	Village Bhatauli Khurd, Sai road, Baddi, District Solan, 173 205
ABDI Ibrahim Ilaç San vs Tic. A.S.	Turkey	Sanayi Mahallesi Tunç Caddesi n°3-Esenyurt,Istanbul
ACCUCAPS INDUSTRIES Ltd Strathroy	Canada	720 Wright street, Strathroy, Ontario N7G 3H8
ACCUCAPS INDUSTRIES Ltd Windsor	Canada	2125 Ambassador Drive Windsor, Ontario N9C 3R5
ACTAVIS LTD Malta	Malta	BLB 016, BLB 026, BLB 010, Bulebel Industrial Estate, Zejutn, ZTN3000
ACTAVIS PHARMA MANUFACTURING PVT Ltd	India	Plot Nos 16, 17, 31 & 32, SIDCO Industrial Estate, (Via) Thiruporur, Kancheepuram District, Alathur 603 110
ACTAVIS PT. INDONESIA	Indonesia	Jalan Raya Bogor Km 28, Jakarta, 13710

MSI QARMA Matrix

QUAMED
Quality Medicine for All

Manufacturer quality

1. Manufacturer GMP Rating Tool ** Summarises ratings of GMP compliance of a manufacturer across all of the key WHO GMP areas **

	Site / Topic Classification Interpretation	Site licensing	QA & Compliance History	Sanitation & hygiene	Validation	Complaints & Recalls	Contracts	Self Inspection	Personnel and training
4 EXCELLENT	Excellent GMP level is established and compliance demonstrated through fine analysis of all documentations and observations	The site is authorized and inspected by the NMRA (reports available that do not contain major observations)	QA system is developped and continously adapted. All required reports are timely available e.g. PQR	S & H program is quite correctly implemented and no finding on cleanliness from the auditor	The VMP is updated and completed : all the validation reports are available and approved	Full periodic reviews are performed on the handling of complaints and, where needed, of recalls with their approved reports	A SOP exists that organize the management of the contracted relationships. 100% of the requested agreements are signed	A detailed SOP, including "for-cause" self-inspections exist. All self-inspections are performed and reported with the corresponding CAPAs	Organogram, job description and training program exist and are updated. The training realization is > 90% and assessed
3 GOOD	Good GMP Compliance is established through the existing systems and documentation but some weaknesses are remaining	The site is authorized and inspected by the NMRA (report available with some observations : few major observations)	QA system is develo[illegible]ed and [illegible]ludes [illegible] modern quality tools including PQRs, however [illegible] SOPs can be missing.	S & H program reinforced with [illegible] SOP [illegible] cleaning of all parts of the site	The VMP is updated and completed [illegible] meaning that all [illegible] are performed. However not all reports are [illegible]	SOP for complaints and recalls handling is complete and [illegible] alerts are documented and where needed recalls are [illegible]	A SOP exists that organize the management of the contracted relationships. [illegible]0% of the requested agreements are signed	Detailed SOP exists together with a program and with a template for reports. Some self-inspections planned are not performed.	Organogram, job description and training program exist and are updated. The training realization is > 80%
2 FAIR	Documentation collected provides some indication of GMP understanding but some basic pieces are wrong or missing	The site is authorized by the NMRA (valid copy of official document available but reports are not disclosed)	QA system exists and includes some other tools like CC and QRM. However corresponding reports can be missing.	S & H program exists generally [illegible] acceptable but housekeeping insufficient	A VMP exists and is maintained. Some validation have been performed but the [illegible] is still in progress	SOP is available for complaints and recalls handling while lacking clearly established responsabilities e.g. for mock-recalls	A SOP exists that organize the management of the contracted relationships. Less than 80% of the requested agreements are signed	Detailed SOP exists and a consistent annual programme is available. However the plan is less than 80% completed.	Organogram, job description and training program exist. However the training is not fully executed (less than 80%)
1 POOR	Assessed topic for the concerned site shows that a number of important GMP requirements are not met or even totally missing	The audited site owns a non-updated manufacturing authorization from its NMRA (outdated copy)	GMP awareness is poor, especially for batch release. QA system includes some tools like CC and deviations but lack modern quality tools	No S & H program and general aspect and housekeeping not entirely satisfactory	Q & V are understood and a simple VMP exists but only some processes are validated or in progress	No formalized SOP for handling of complaints but some records can be presented	Unclear description of services contracted. Less than 50% of the requested agreements are signed	No detailed SOP on self-inspections. Some kind of self-inspections exist but poorly organized and documented	Organogram exists but no job descriptions. Training program exists but is not adapted to the competencies
0 UNACCEPTABLE	Available information provides evidence of a lack of GMP understanding for the corresponding topic or information is not available	A proof of authorization (licence) is not available	GMP are not really known. There is no real QA system and there are no quality tools like IPC, CC or deviation iinvestigation	No S & H program. General aspect and organization very weak	Notions of Q & V are poorly understood. No VMP document is available	No formalized SOP for handling of complaints and absence of a complaint/recall register	Unclear description of services contracted. Less than 20% of the requested agreements are signed	No SOP. Self inspection obviouly not done	No organogram. No job description. No recruitement based on needed competencies. No training program

+

Product dossier quality

2. MSI QUAPAS Tool: Summary Table ** Summarises ratings of product dossier for a product across the key dossier areas **

	REGISTRATION	FINISH PRODUCT	STABILITY	LABELING/ PACKAGING/ LEAFLET	SAFETY AND EFFICACY	API
4 EXCELLENT	Product registered on a HR market	Complying with BP / USP / IP + general tests+ additional tests (validated) Or Stringent IH specifications + validated method (no monograph)	Complying with ICH zone 4 and consistent with proposed shelf life	Complying with WHO recommendations - Tri language	No BE needed Or Satisfactory in vitro study dossier - (in vitro sufficient) Or Satisfactory in vivo study - qualified CRO (in vivo necessary)	Additional information (technical file) or additional guarantee of quality (Valid CEP) + 2 consistent CoAs
3 GOOD	Product approved by QUAMED recognized body	BP / USP / IP specific monograph + general tests Or [illegible] IH specifications + description (no monograph)	Complying with ICH zone 3 and consistent with proposed shelf life	Complying with WHO recommendations - Bi language	Satisfactory in vivo study - non-qualified CRO (in vivo necessary)	Satisfactory specifications (Ph or IH) + general tests + 2 consistent CoAs
2 FAIR	Product registered in the country of origin (non HR)	BP / USP / IP specific monograph Or Satisfactory IH specifications (no monograph)	On-going stabilities complying with ICH but insufficient to cover shelf life	Complying with WHO recommendations - Mono language	In vitro study dossier available and compliant with WHO standards but some minor deficiencies (in vitro sufficient) Or In vivo study dossier available and conform to WHO standards - but some minor deficiencies (in vivo necessary)	Satisfactory specifications (Ph or IH)+ 1 consistent CoA
1 POOR	Product registered in a non HR country and not in the country of origin	Not complying with BP / USP / IP Or Unsatisfactory IH specifications (no monograph)	Unsatisfactory studies	Weak labeling/packaging/leaflet - major deficiencies	In vitro study not compliant with WHO standards (in vitro sufficient) Or No in vivo study available, but satisfactory in vitro dossier (in vivo needed)	Unsatisfactory specifications / CoA but API manufacturer identified
0 UNACCEPTABLE	Product not registered in any country	Unknown specifications	No stability data	Unacceptable labeling/packaging/leaflet - critical deficiencies	No study / Unacceptable study	Unidentified sources

+

Product characteristics

3. MSI Product-Specific Characteristics Risk Classification Tool ** Quantifies inherent risk of a specific product according to its manufacture and clinical use **

KEY SRH PRODUCTS	STERILE DOSAGE FORM	8	COMPLEX MFG PROCESS	4	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	128	HIGH
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	64	HIGH
			STANDARD MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	64	HIGH
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	32	MED
	NON STERILE DOSAGE FORM	4	COMPLEX MFG PROCESS	4	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	64	HIGH
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	32	MED
			STANDARD MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	32	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	16	MED
KEY ANCILLARY PRODUCTS	STERILE DOSAGE FORM	4	COMPLEX MFG PROCESS	4	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	64	HIGH
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	32	MED
			STANDARD MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	32	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	16	MED
	NON STERILE DOSAGE FORM	2	COMPLEX MFG PROCESS	4	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	32	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	16	MED
			STANDARD MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	16	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	8	LOW
OTHER ANCILLARY PRODUCTS	STERILE DOSAGE FORM	2	COMPLEX MFG PROCESS	4	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	32	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	16	MED
			STANDARD MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	16	MED
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	8	LOW
	NON STERILE DOSAGE FORM	1	COMPLEX MFG PROCESS	2	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	8	LOW
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	4	LOW
			STANDARD MFG PROCESS	1	SENSITIVE ACTIVE SUBSTANCE	4	QA REQUIREMENTS	4	LOW
					STANDARD ACTIVE SUBSTANCE	2	QA REQUIREMENTS	2	LOW

STERILE DOSAGE	COMPLEX PROCESS	SENSITIVE ACTIVE SUBSTANCE
Injectable products	Fixed-dose combination	Narrow therapeutic index
Irrigation products	Modified release products	Polymorphism
Eye Care products	Aseptic manufacturing	Low stability
Implantable products	Very low dosage formulations	

=

** Quantifies overall latent risk of using a product, based on the three key components **

MATRIX		PRODUCT DOSSIER QUALITY [2]				
		A: Excellent	B: Good	C: Fair	D: Poor	E: Unacceptable
MANUFACTURING QUALITY [1]	A: Excellent	Low	Low	Low	Low	Low
		Medium	Medium	Medium	Medium	Medium
		High	High	High	High	High
	B: Good	Low	Low	Low	Low	Low
		Medium	Medium	Medium	Medium	Medium
		High	High	High	High	High
	C: Fair	Low	Low	Low	Low	Low
		Medium	Medium	Medium	Medium	Medium
		High	High	High	High	High
	D: Poor	Low	Low	Low	Low	Low
		Medium	Medium	Medium	Medium	Medium
		High	High	High	High	High
	E: Unacceptable	Low	Low	Low	Low	Low
		Medium	Medium	Medium	Medium	Medium
		High	High	High	High	High

OVERALL RISK:		
	Green	Very low risk of quality issues of these products
	Light green	Low risk of quality problems with these products
	Amber	Medium risk of quality problems with these products. QC testing requirements would be moderate.
	Light red	High risk products. QC testing requirements quite extensive
	Red	Very high risk products and not recommended for use

Insight #5

Product quality falls in a hole if you don’t have clear accountabilities

Quality is everybody's responsibility

Product Committee

We recommend establishing, within your MAT, a small *Product Committee* that meets when required to review and decide on product QA matters and maintain your Standard Products List. The committee would report to the MAT. Below is an example of who this committee could include and the scope of work that they could be responsible for.

Members of committee	Tasks of committee
• designated lead for clinical quality (Chair) • procurement manager • logistics or warehouse manager • a service delivery channel manager • another senior clinician • programme pharmacist* (where available)	• Developing and reviewing your Standard Products List • Ensuring Q-Trak is up to date Reviewing and managing product related incident reports • Supplier assessments • Ensuring minimum quality criteria for medical goods procurement are met when evaluating bids • Evaluation of physical samples in procurement process • All other matters relating to product quality

Product Quality Toolkit



Understanding Product Quality – Quality Control Testing

Quality Control testing

Quality Control testing (sometimes referred to as batch testing) is laboratory testing conducted to check if a product meets all of the specifications that it is supposed to meet. It checks whether the QA measures of the manufacturer were followed and were effective.

QC testing is routinely carried out by the manufacturer during production (the *Certificate of Analysis* is then produced to demonstrate compliance – see below), but can also be carried out by the buyer after they purchase the product. This testing can be **pre-shipment** (before the product is sent to the buyer) or **post-shipment** (after the product is already in your programme).

QC testing can tell you if the product is of acceptable quality **at the time it is tested, according to what was tested.** It may miss impurities or contamination, degradation that may later occur, and doesnt tell you if the sample tested is representative of the entire batch. QC on its own is not sufficient QA and must be supported by GMP and dossier assessment.

A satisfactory QC testing result is not a guarantee that a product will be acceptable until the end of its shelf life. It means that it should be acceptable now. See the real example [below] where pre-shipment testing of 3 batches of Misoclear was OK, but post-shipment testing showed that the tablets were degrading quickly.



QC Testing Parameters for a tablet

Integrated incident reporting



MARIE STOPES INCIDENT NOTIFICATION FORM

Instructions: This form requires basic information about the incident and is NOT an investigation. This form should be completed and submitted to the designated clinical quality lead following an incident. Red incidents must be reported to Support Office and escalated to Global MDT within 24 hours. Green and amber incidents must be reported to Support Office within 48 hours.

1. Initial details	Date of incident (dd/mm/yyyy)	
	Programme	
	Name of site or team	
	Service channel: Marie Stopes RH centre; Social franchise; Outreach Team; MS Ladies; MSI Obstetric centre; Obstetrics SF; Obs. Voucher Mgmt. Agency; Other	
	If "other" for service channel, please describe here:	
2. Client details	INITIALS of client and their client record number	
	Gender	
	Age	
	Gestational age in weeks (if applicable)	
	Service: Injectable; Implant; IUD/IUS; Mini-lap TL; Laparoscopic TL; Surg. SAC <14 wks; Med. SAC <14 wks; Surg. SAC >14 wks; Med. SAC >14 wks; MSV; Non-core or general medical; Obstetrics - Caesarean; Obstetrics - Normal delivery; Obstetrics - Other; Other	
	Obstetrics Client Type: Antenatal client; Client for delivery; Postnatal client	
	If Obstetrics, booked/unbooked client?	
	Eventual outcome (for adult): Fatality; No fatality; Unknown	
	Eventual outcome for neonate (if applicable): IUFD; Neonatal death; Stillbirth; No fatality; Unknown; Not applicable	
	Drug reaction; Obs-Antepartum haemorrhage	

Instructions | 1. INF Form | 1.a PRIF | PRIF examples | INF Data | PRIF Data | Risk Rating Gu



Instructions: Please complete this form for product-related incide

PRODUCT RELATED INCIDENT FORM

Instructions: Please complete this form for product-related incidents. Please note that if you have also completed the "1. INF Form" tab, clicking the "Complete PRIF" button at the bottom of the notification form will autopopulate the PRIF fields below.

1. Initial details	Date of incident (dd/mm/yyyy)	
	Programme	
	Name of site or team	
	Service channel	
	Type of incident	
2. Client Information (*note: does not need to be completed if the incident does not involve a client*)	Initials AND client record #	
	Gender	
	Age	
	Weight (kg)	
	Gestational age in weeks (if applicable)	
	Breastfeeding at time of incident?	
	Other relevant medical history *E.g. date of last period; allergies; medical conditions; etc*	
3. Suspected product information	Product description *specify brand name; generic name or product type; strength; dosage form; other relevant product details*	
	Manufacturer	
	Batch/Lot #	
	Expiry date	
	Indication	
	Dosing/administration details: *E.g. dose, route of admin, how prepared*	
	Date started/inserted: (dd/mm/yyyy) *(if medicine; estimate if unsure)*	
	Date stopped: (dd/mm/yyyy)	
	Other medicines taken at time of incident: *(exclude those used to treat reaction; include dates started & stopped)*	
4. Risk Rating (if also a clinical incident)		
	Service	
	Brief Description (2-3 sentences)	
	Additional information and incident	

Instructions | 1. INF Form | 1.a PRIF | PRIF examples | INF Data | PRIF Data | Risk Rating Guid

Insight #6

Supply planning & monitoring is critical to improve access

Programme Standard Products Lists including approved products



A1 | Standard Products List: Myanmar v2016

Standard Products List: Myanmar v2016

	DATA		PRODUCT DETAILS		THERAPEUTIC	SERVICES										CHANNELS				QUALITY	
	Product Code	Product Category	Product name	Unit	Therapeutic Category (WHO)	IUD	Implant Insertion	Inject-able	STI	STI plus	MEM int	ANC	MSP	General Med	IP	OR Class	Centre Class	Centre Extended	Social Marketing	Approved Manufacturer / Wholesaler/Product	Quality Category
4	TCODE_ACIT200	2MED	aciclovir 200mg tab	tablet	06.4 Antivirals					X						X		X		per MSIM Approved List	Key ancillary
5	EADPPC7	5EQPT	adaptor double valve 7mm pcs	pieces	33. Diagnostic Equipment								X					X		MSI GSC	KeySRH
6	EADPPC8	5EQPT	adaptor double valve 8mm pcs	pieces	34. Medical Equipment								X					X		MSI GSC	KeySRH
7	MADRIJ1	2MED	adrenaline 1:1000 amp	ampoule	03. Antiallergics & Anaphylaxis						X					X	X	X		per MSIM Approved List	Key ancillary
11	TCODE_AMXC500	2MED	amoxicillin 500mg cap	capsule	06.2 Antibacterials											X	X	X		per MSIM Approved List	Key ancillary
12	MATRI05	2MED	atropine 0.5-0.6mg/ml amp	ampoule	04. Antidotes & used in Poisonings						X					X	X	X		per MSIM Approved List	Key ancillary
13	TCODE_AZMT500	2MED	azithromycin 500mg tab	tablet	06.2 Antibacterials				X							X	X	X		per MSIM Approved List	Key ancillary
14	TCODE_BZTI24	2MED	benzathine pen 2.4MIU vial	vial	06.2 Antibacterials				X							X	X	X		per MSIM Approved List	Key ancillary
15	ECNLPC4	5EQPT	cannula no 4 pcs	pieces	34. Medical Equipment	X										X	X	X		MSI GSC	KeySRH
16	ECNLPC5	5EQPT	cannula no 5 pcs	pieces	34. Medical Equipment								X					X		MSI GSC	KeySRH
17	ECNLPC6	5EQPT	cannula no 6 pcs	pieces	34. Medical Equipment								X					X		MSI GSC	KeySRH
18	ECNLPC7	5EQPT	cannula no 7 pcs	pieces	34. Medical Equipment								X					X		MSI GSC	KeySRH
19	TCODE_CFXT200	2MED	cefixime 200mg tab	tablet	06.2 Antibacterials				X					X		X	X	X		per MSIM Approved List	Key ancillary

tracker | guidance | master list | service by channel | IUD | Impl Ins | Impl Rem | Injectable | OC & EC | Condom | STI | STI plus | MEM Basic | MEM int | Lab test | Child Health | ANC | Cryo & HPV | VIA | GBV | PAC

Other measures to improve access

- Development of supply plans
  - annual planning of allocated supplies versus needs
  - quarterly stock status reporting and review against plans
- Donor engagement to increase donated commodities available
- Introduction of stock-out indicators
- Working closely with MoH on planning, allocations, and supply


LETs HAVE A HAPPY FAMILY WITH MARIE STOPES. AFGHANISTAN
MARIE STOPES INTERNATIONAL

THANK YOU!